Agenus reports Q3 results
at seekingalpha.com (Thu, 5-Nov 7:36 AM)
Agenus highlights a three-year survival plateau for BOT+BAL in heavily pretreated recurrent ovarian cancer
Market Chameleon (Mon, 5-Oct 8:14 AM)
